FDA approves Keytruda + chemoradiotherapy for FIGO 2014 stage 3-4A cervical cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved Keytruda (pembrolizumab) with chemoradiotherapy for patients with FIGO 2014 stage 3-4A cervical cancer.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents


FDA has accepted the supplemental New Drug Application for Augtyro (repotrectinib) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity.